Objective: We investigated the association of positive peritoneal cytology with prognosis in uterine cervical cancer. Study Design: We reviewed the medical records and cytologic materials of 225 Japanese patients with FIGO IB1-IVB uterine cervical cancer who had undergone surgery at our University Hospital between 1993 and 2012. Univariate and multivariate regression analyses were performed for statistical analysis. Results: Positive peritoneal cytology was noted in 6 of 225 patients (2.7%). Positive peritoneal cytology was found in 4 of 149 patients (2.6%) with squamous cell carcinoma (SCC) and in 2 of 70 patients (2.8%) with non-SCC (p = 0.9434). The 5-year survival rate of patients with positive peritoneal cytology was significantly lower than that of patients with negative cytology (50 vs. 84.6%, p = 0.001) in univariate survival analysis. However, peritoneal cytology no longer remained significant in multivariate analysis. Conclusion: Although we conclude that positive peritoneal cytology in uterine cervical cancer is a poor prognostic factor, further investigation and multi-institutional studies are necessary.

Keywords:
Uterine cervical cancer, Peritoneal cytology, Prognosis
1.
Estape R, Angioli R, Wagman F, Madrigal M, Janicek M, Ganjei-Azar P, Penalver M, Averette H: Significance of intraperitoneal cytology in patients undergoing radical hysterectomy. Gynecol Oncol 1998;68:169-171.
2.
Imachi M, Tsukamoto N, Matsuyama T, Nakano H: Peritoneal cytology in patients with carcinoma of the uterine cervix. Gynecol Oncol 1987;26:202-207.
3.
Kashimura M, Sugihara K, Toki N, Matsuura Y, Kawagoe T, Kamura T, Kaku T, Tsuruchi N, Nakashima H, Sasaki H: The significance of peritoneal cytology in uterine cervix and endometrial cancer. Gynecol Oncol 1997;67:285-290.
4.
Takeshima N, Katase K, Hirai Y, Yamawaki T, Yamauchi K, Hasumi K: Prognostic value of peritoneal cytology in patients with carcinoma of the uterine cervix. Gynecol Oncol 1997;64:136-140.
5.
Kasamatsu T, Onda T, Sasajima Y, Kato T, Ikeda S, Ishikawa M, Tsuda H: Prognostic significance of positive peritoneal cytology in adenocarcinoma of the uterine cervix. Gynecol Oncol 2009;115:488-492.
6.
Kuji S, Hirashima Y, Komeda S, Tanaka A, Abe M, Takahashi N, Takekuma M: The relationship between positive peritoneal cytology and the prognosis of patients with FIGO stage I/II uterine cervical cancer. J Gynecol Oncol 2014;25:90-96.
7.
Abu-Ghazaleh S, Johnson W, Creasman WT: The significance of peritoneal cytology in patients with carcinoma of the cervix. Gynecol Oncol 1984;17:139-148.
8.
Trelford JD, Kinney W, Vogt P: Positive peritoneal cytology in stage I carcinoma of the cervix. Acta Cytol 1995;39:177-179.
9.
Roberts WS, Bryson SC, Cavanagh D, Roberts VC, Lyman GH: Peritoneal cytology and invasive carcinoma of the cervix. Gynecol Oncol 1986;24:331-336.
10.
Morris PC, Haugen J, Anderson B, Buller R: The significance of peritoneal cytology in stage IB cervical cancer. Obstet Gynecol 1992;80:196-198.
11.
Ito K, Noda K: Peritoneal cytology in patients with uterine cervical carcinoma. Gynecol Oncol 1992;47:76-79.
12.
Zuna RE, Hansen K, Mann W: Peritoneal washing cytology in cervical carcinoma: analysis of 109 patients. Acta Cytol 1990;34:645-651.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.